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Background
Pharmacovigilance studies are helpful to follow the use
of allergen immunotherapy in clinical practice. Indust-
rially manufactured allergen vaccines (VALERGEN) of
three mite species (including the tropical species Der-
matophagoides siboney and Blomia tropicalis) have been
recently introduced country-wide in Cuba for asthma
treatment. To assess the safety and efficacy of allergen
immunotherapy by injection or sublingual routes, using
VALERGEN vaccines in the routine clinical practice.
Methods
A national prospective study was conducted using the
cohort adverse event monitoring method. Patients have
been followed at least for 12 months. The study has
included 2108 asthmatic patients above 5 years old,
attending 24 allergy services in 10 provinces. Efficacy
variables were measured using a standard questionnaire,
reporting data on the last two weeks prior to the
administration.
Results
52.5% of included patients received SLIT and 47.5%
SCIT, 51.3% were children. Overall, 101 adverse reac-
tions were reported. The frequency of local reactions
per administration was 0.16% and 0.013%, for SCIT and
SLIT, respectively; whereas the frequency of systemic
reactions was significantly greater for SCIT (0.204%)
versus SLIT (0.003%). All systemic reactions by SLIT
were classified as mild whereas 2 severe (Grade IV)
reactions were reported by SCIT. The frequency of both
local and systemic reactions was significantly greater in
adults as compared to children. On the other hand, sig-
nificant increase of Quality of Life index, decrease of
asthma severity and frequency of asthma manifestations
and drug consumption was found, as compared to pre-
treatment values for both administration routes in a
similar extent.
Conclusions
The results confirm the efficacy of SCIT and SLIT using
standardized house dust mite allergen vaccines for
asthma treatment, as well as the higher safety profile of
the sublingual route.
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